A Review on Venetoclax – An Antineoplastic Agent

Vendra S R
2017 Journal of Medical Science And clinical Research  
This review will focus on the drug information of Venetoclax, a small molecule oral drug that treats chronic lymphocytic leukemia (CLL) in those with a specific chromosomal abnormality, in adults with 17p deletion. Venclexta is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) proteins, which supports cancer cell growth and is over expressed in many patients with CLL. Venetoclax is used a second line treatment for chronic lymphocytic leukemia, only if there is a 17p
more » ... f there is a 17p deletion. Venclexta (venetoclax) inhibits a certain protein in cancer cells (abnormal lymphocytes produced in chronic lymphocytic leukemia) that helps keep those cells alive and makes them resistant to chemotherapy. Venetoclax binds to this protein, which helps kill the cancerous lymphocytes in blood and bone marrow. Venclexta is usually given after at least one other cancer medicine has been tried without success.
doi:10.18535/jmscr/v5i4.45 fatcat:l4yxbiyz4rawtbr3ewcsrzfaoi